TABLE 2.

Patient characteristics and detailed information in the targeted therapy plus SS group

Case	Gender	Age (years)	Histology	Gene mutation type	CS before targeted therapy	Distant metastasis	Targeted drug	Drug duration	CS after targeted therapy
1	F	63	AD	19‐Del	cT2N2M1c,IV	Liver, Ribs	Gefitinib	9 months	cT2N0M0,IB
2	F	36	AD	19‐Del	cT4N2M1a,IV	Contralateral lung, Pleura	Gefitinib	7 months	cT2N0M0,IB
3	F	59	AD	19‐Del	cT1cN2M1a,IV	Malignant effusion	Gefitinib	7 months	cT1bN0M0,IA
4	M	48	AD	19‐Del	cT2aNxM1a,IV	Multiple lungs	Gefitinib	4 months	cT1N0M0,IA
5	M	58	AD	19‐Del	cT1cNxM1a,IV	Multiple lungs	Gefitinib	3 months	cT1bN0M0,IA
6	M	51	AD	19‐Del	cT4N2M0,IIIB	—	Gefitinib	2 months	cT1N0M0,IA
7	M	32	AD	19‐Del	cT1cN3M0,IIIB	—	Gefitinib	2 months	cT1bN0M0,IA
8	M	45	SC	ALK	cT3N3M0,IIIC	—	Crizotinib	2 months	cT1N0M0,IA
9	F	59	ADCA	19‐Del	cT2N3M0,IIIB	—	Gefitinib	2 months	cT1N0M0,IA
10	M	48	AD	L858R	cT2N2M1b,IV	Ilium	Gefitinib	2 months	cT1N0M0,IA
11	F	59	AD	L858R	cT4N0M1a,IV	Multiple lung	Gefitinib	2 months	cT1N0M0,IA
12	F	67	AD	ALK	cT3N2M0,IIIB	—	Crizotinib	2 months	cT1N0M0,IA
13	F	55	AD	19‐Del	cT2N2M1a,IV	Contralateral lung	Gefitinib	2 months	cT1N0M0,IA
14	M	54	AD	L858R	cT3N2M0,IIIB	—	Gefitinib	2 months	cT1N0M0,IA
15	M	56	AD	19‐Del	cT3N2M0,IIIB	—	Gefitinib	2 months	cT1N0M0,IA
16	M	60	AD	19‐Del	cT3N3Mx,IIIC	—	Gefitinib	2.5 months	cT2N0M0,IB
17	F	65	AD	L858R	cT2N2M1a,IV	Contralateral lung	Gefitinib	12 months	cT2N0M0,IB
18	F	61	AD	L858R	cT2N2M1a,IV	Contralateral lung	Gefitinib	3 months	cT1N0M0,IA

Abbreviations: AD, adenocarcinoma; ADCA, adenosquamous carcinoma; CS, clinical stage; F, female; M, male; SC, squamous carcinoma.